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ABSTRACT
Dysregulation of transforming growth factor-β1 (TGF-β1) and insulin-like growth 
factor (IGF) axis has been linked to reactive stroma dynamics in prostate cancer 
progression. IGF binding protein-3 (IGFBP3) induction is initiated by stroma remodeling 
and could represent a potential therapeutic target for prostate cancer. In previous 
studies a lead quinazoline-based Doxazosin® derivative, DZ-50, impaired prostate tumor 
growth by targeting proteins involved in focal adhesion, anoikis resistance and epithelial-
mesenchymal-transition (EMT). This study demonstrates that DZ-50 increased expression 
of the epithelial marker E-cadherin, and decreased the mesenchymal marker N-cadherin 
in human prostate cancer cells. In DU-145 cells, the effect of DZ-50 on EMT towards 
mesenchymal epithelial transition (MET) was inhibited by talin1 overexpression, a focal 
adhesion regulator promoting anoikis resistance and tumor invasion. DZ-50 treatment 
of human prostate cancer cells and cancer-associated fibroblasts (CAFs) downregulated 
IGFBP3 expression at mRNA and protein level. In TGF-β1 responsive LNCaPTβRII, TGF-β1 
reversed DZ-50-induced MET by antagonizing the drug-induced decrease of nuclear 
IGFBP3. Furthermore, co-culture with CAFs promoted prostate cancer epithelial cell 
invasion, an effect that was significantly inhibited by DZ-50. Our findings demonstrate that 
the lead compound, DZ-50, inhibited the invasive properties of prostate cancer epithelial 
cells by targeting IGFBP3 and mediating EMT conversion to MET. This study integrated 
the mechanisms underlying the effect of DZ-50 and further supported the therapeutic 
value of this compound in the treatment of advanced metastatic prostate cancer.
INTRODUCTION
Prostate cancer accounts for 21% of cancer 
diagnoses and 8% of cancer-related deaths in men 
with a total of 180,890 new cases and 26,120 deaths 
estimated in 2016 in the United States [1]. Advances in 
diagnostic, surgical and radiotherapy approaches have 
been shown to have a significant impact on impairing 
tumor progression and improve patient survival [2]. 
Androgen deprivation therapy (ADT) including medical 
or surgical castration remains the primary treatment 
option for prostate cancer patients with metastatic disease 
[3, 4]. However, after ADT the majority of patients 
eventually develop castration-resistant prostate cancer 
(CRPC) [4, 5]. The recognition that CRPC is driven by 
aberrant androgen signaling and androgen receptor (AR), 
led to the utilization of AR-directed second generation 
antiandrogens, abiraterone and enzalutamide for the 
treatment of metastatic CRPC (mCRPC) [5, 6]. Taxanes, 
including docetaxel and cabazitaxel, are 1st and 2nd line 
chemotherapy respectively, for the treatment of patients 
with mCRPC developing resistance to ADT [7], and 
contribute to only a modest improvement of survival 
[8–10]. Overriding this resistance requires understanding 
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of the driving mechanisms, besides the AR in CRPC in the 
context of the tumor microenvironment and development 
of targeted therapeutics.
The heterogeneity characterizing the prostate 
gland consists of luminal epithelial cells, basal cells 
and a small number of neuroendocrine cells among the 
epithelium in the surrounding stroma [11]. The reactive 
prostate stroma within the microenvironment functionally 
contributes to prostate cancer initiation, progression 
and metastasis [12]; with stroma-derived transcriptome 
signatures shown to be of strong predictive value of patient 
survival, disease progression and therapeutic resistance 
[12]. Normal fibroblasts maintain tissue homeostasis, 
however, myofibroblasts and cancer-associated fibroblasts 
(CAFs) facilitate tumor progression via their repair-centric 
system and pro-survival biology, promoting tumor growth 
and vascularity [13]. Taking control of the dynamics of 
prostate stroma microenvironment is the multifunctional 
cytokine transforming growth factor-β1 (TGF-β1); 
activation of TGF-β1 signaling mediates the transition of 
fibroblast to myofibroblasts [14] and promotes prostate 
cancer cell-mediated differentiation of normal fibroblasts 
into CAFs towards metastasis [13, 15].
Additional growth factor signaling networks 
contextual to the tumor microenvironment are functionally 
involved in prostate tumor growth and progression 
including the insulin growth-factor (IGF) signaling 
axis [16, 17]. IGF ligand binds to the IGF-I receptor, a 
transmembrane tyrosine kinase receptor, and subsequently 
IGF-II receptor to activate downstream signaling cascades, 
such as AKT, promoting cell proliferation and survival 
[16]. Stimulation of the IGF-I axis up-regulates zinc 
finger E-box-binding protein1 (ZEB1) which promotes 
the process of epithelial-mesenchymal-transition (EMT) in 
human prostate cancer cells [18]. EMT is characterized by 
loss of epithelial protein E-cadherin and upregulation of 
mesenchymal proteins (N-cadherin and vimentin); ZEB1 
facilitates EMT by acting as a transcriptional repressor 
of E-cadherin expression [18], towards invasion and 
metastasis. A clinically significant increase in serum and 
prostatic tissue levels of IGF ligands has been detected 
in prostate cancer patients [16]. IGFs also bind to IGF-
binding proteins (IGFBPs), with IGFBP3 being the most 
abundant carrier of IGF ligands in serum [16, 17]. IGFBP3 
inhibits IGF signaling due to high-affinity binding to 
IGFs and subsequent sequestration of the ligand or due 
to IGF-independent mechanisms [16, 17]. Moreover, 
IGFBP3 can promote IGF action in diverse human 
cells including skin fibroblasts [19], breast carcinoma 
cells [20] and prostate cancer cells overexpressing a 
constitutively active AR [21]. Mechanistic dissection in 
cultured fibroblasts indicated that IGFBP3 potentiates 
IGF action via the phosphatidylinositol-3-kinase pathway 
[22]. In human esophageal epithelial cells, IGFBP3, 
in an IGF independent mechanism, promotes TGF-β1-
mediated EMT and activates transcriptional regulators 
essential in EMT, including snail, ZEB1 and ZEB2 [23]. 
Specifically, IGFBP3 loss suppressed TGF-β1-mediated 
EMT, while IGFBP3I56G/L80G/L81G, a mutant IGFBP3 lacking 
IGF binding capacity, prevented the IGFBP3 knockdown 
effect. Furthermore, IGFBP3I56G/L80G/L81G promoted EMT 
in vivo in a Ras-transformed esophageal xenograft model 
[23], implicating an IGF independent action of IGFBP3 to 
promote EMT.
Our previous studies on the structural optimization 
of the quinazoline-based α1-adrenoceptor antagonist 
Doxazosin®, led to the generation of a lead derivative, 
DZ-50, that impaired prostate tumor growth through 
anoikis [24, 25]. A genome-wide microarray analysis and 
pathway association analysis of pre-clinical models [24] 
identified that DZ-50 down-regulated genes encoding 
regulators of extracellular matrix (ECM), tight junctions, 
angiogenesis, and a component of IGF axis involved in 
prostate stroma remodeling (IGFBP3) [14]. The present 
study focused on characterizing the role of IGFBP3 in 
TGF-β1-mediated EMT and reversal to MET in response 
to the drug. We found that DZ-50 antagonized TGF-
β1-promoted cell invasion by targeting IGFBP3 in both 
prostate cancer epithelial cells and CAFs, supporting its 
therapeutic value.
RESULTS
Induction of MET in prostate cancer epithelial 
cells by DZ-50
Cell viability of DU-145 and DU-145talin1 was 
decreased by DZ-50 in a concentration dependent manner 
(Figure 1A). Our previous studies demonstrated that DZ-
50 at 5µM downregulated talin1 expression and drug-
induced anoikis was prevented by talin1 overexpression 
[24]. In the current study, the ability of DZ-50 to reduce 
cell viability after 48hrs of treatment was compromised 
by talin1 overexpression. The effect of DZ-50 on 
mRNA expression of IGFBP3, E-cadherin, N-cadherin, 
Vimentin, Slug/Snail (E-cadherin repressor), and ZEB1 
was subsequently profiled (Figure 1B). Within 3hrs of 
treatment there was a significant decrease in IGFBP3 
mRNA expression, and an increase in E-cadherin mRNA. 
A temporal decrease in mRNA levels for N-cadherin, 
vimentin and slug was detected after 6hrs of exposure 
to the drug. DZ-50-induction of E-cadherin mRNA and 
downregulation of N-cadherin, slug and snail mRNA were 
prevented by elevated talin1 (Figure 1B). Phenotypic EMT 
profiling in DU-145 and DU-145talin1 cells revealed that 
DZ-50 (2µM; 48hrs) decreased IGFBP3, N-cadherin, 
ZEB1 and vimentin protein expression (Figure 1C). 
The effect of DZ-50 on N-cadherin and vimentin was 
antagonized by talin1 overexpression (Figure 1C).
The human prostate cancer cells LNCaP, lack TGF-β 
type II receptor and thus are refractory to effect of TGF-β1; 
genetically-engineered overexpression of the type II 
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receptor restores sensitivity of LNCaP cells to TGF-β1 
[26, 27]. Treatment with DZ-50 significantly inhibited 
cell viability in both the LNCaP and LNCaPTβRII cells 
in a concentration- and time-dependent manner (Figure 2, 
panels A and B respectively); this effect of the drug was 
antagonized by TGF-β signaling in the LNCaPTβRII cells 
after 48 hrs of exposure to DZ-50. Further reduction in 
cell viability in these cells was observed after 96hrs of 
treatment. Expression profiling of the candidate targets 
revealed that DZ-50 decreased IGFBP3 mRNA expression 
within 3hrs of treatment (Figure 2C) with a consequential 
decrease in IGFBP3 protein levels (by 24hrs) (Figure 2D) 
in the LNCaP, but not in the LNCaPTβRII cells. There 
was reduced N-cadherin protein expression, paralleled 
by elevated E-cadherin after 48hrs of drug exposure 
(Figure 2D), indicating a reversal to epithelial phenotype 
(MET). The intrinsically active TGF-β signaling in 
the LNCaPTβRII prostate cancer cells antagonized 
the inhibitory effect of DZ-50 on IGFBP3 expression. 
Expression of ZEB1, AR and β-catenin was not affected 
by the drug (Figure 2D).
We subsequently investigated the functional 
consequences of IGFBP3 loss on the sensitivity of 
LNCaPTβRII cells to DZ-50. As shown on Figure 2 
(panels E and F), IGFBP3 knockdown led to E-cadherin 
mRNA and protein upregulation and a modest N-cadherin 
mRNA decrease. The effect of IGFBP3 loss on E-cadherin 
mRNA was prevented by DZ-50 exposure (Figure 2G). 
No significant differences were detected in mRNA 
expression for Snail and ZEB1 by IGFBP3 knockdown 
regardless of the presence of DZ-50 (Figure 2E and 2G). 
IGFBP3 knockdown however enhanced the sensitivity 
of LNCaPTβRII cells to the drug, further reducing cell 
viability (Figure 2H).
Figure 1: Effect of DZ-50 on prostate cancer cell death and EMT. Panel A, indicates the response of human prostate cancer cells 
to increasing concentrations of DZ-50. Cell viability was inhibited in both DU-145 and DU-145talin1 cells in a dose- and time-dependent 
manner by DZ-50, n=4;*p<0.05. Panel B, reveals the mRNA expression profile of EMT regulators IGFBP3, E-cadherin (E-cad), N-cadherin 
(N-cad), vimentin (Vim), Slug, Snail and ZEB1 in response to DZ-50 (2µM). mRNA levels were determined by RT-PCR; n≥6; *p<0.05. 
Panel C, Effect of DZ-50 on IGFBP3, E-cadherin, N-cadherin, β-catenin, vimentin, talin1 and ZEB1 protein expression (by Western blot).
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Figure 2: Functional involvement of IGFBP3 in the reversion of EMT to MET in prostate cancer cells. Panels 
A and B, reveal the dose response and time course of DZ-50 treatment of prostate cancer cells LNCaP and LNCaPTβRII. DZ-50 
decreased cell viability in both cell lines; n=4; *p<0.05 compared to control. Panel C, indicates the effect of DZ-50 (4 µM) on 
IGFBP3 mRNA; n = 6. *p<0.05. Panel D, Western blot analysis of ZEB1, E-cadherin, N-cadherin, AR, β-catenin, and IGFBP3 
protein levels in response to DZ-50 (4 µM, 24-48hrs). Panels E and F, shows the consequences of IGFBP3 loss on EMT regulators 
mRNA (by RT-PCR) and protein expression (by Western blot); n = 5. *p<0.05. Panel G, the effect of DZ-50 (3hrs; 4µM) on mRNA 
expression after IGFBP3 knockdown (n=5; *p<0.05). Panel H, reveals the effect of IGFBP3 silencing on LNCaPTβRII cell response 
to DZ-50 (4µM, 48hrs); n=3; *p<0.05.
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DZ-50 decreased nuclear expression of IGFBP3 
in LNCaPTβRII cells
LNCaP and LNCaPTβRII cells were treated with 
DZ-50 (4µM) for 24hrs in the presence or absence of 
TGF-β1 (5ng/ml), and subjected to confocal microscopy. 
For both the LNCaP and LNCaPTβRII cells, E-cadherin 
was primarily localized on cell membrane regardless of 
the presence of the drug (Supplementary Figure 1A and 
Figure 3A). IGFBP3 was distributed in both cytoplasmic 
and nuclear fractions of the cells (Supplementary Figure 1A 
and Figure 3A), with a predominant nuclear localization in 
LNCaPTβRII cells (Figure 3A). DZ-50-induced membrane 
localization of IGFBP3 and E-cadherin was inhibited by 
TGF-β1 in these cells (Figure 3A); in LNCaP cells there was 
no apparent effect by TGF-β1 (Supplementary Figure 1A).
Western blot analysis of protein in subcellular 
fractions from LNCaPTβRII cells, revealed that TGF-β1 
increased cytosolic IGFBP3 levels with no effect on 
nuclear protein. Treatment with DZ-50 decreased IGFBP3 
expression in the nuclear, while it increased IGFBP3 
levels in the cytosol (Figure 3B). DZ-50 treatment in 
the presence of TGF-β1, sustained elevated cytosolic 
IGFBP3, but had no effect on nuclear levels. The above 
change of the fractional expression of IGBFP3 resulted 
in the diffused distribution of the protein by the drug 
alone or in combination with TGF-β1 as shown by 
confocal microscopy (Figure 3A). In LNCaP cells, DZ-
50 decreased nuclear IGFBP3 levels, with no apparent 
effect on cytosolic protein levels regardless of TGF-β1 
presence (Supplementary Figure 1B). There was no effect 
on IGFBP3, AR, E- and N-cadherin in LNCaP cells by 
TGF-β1 (Supplementary Figure 2). TGF-β1 led to reduced 
E-cadherin and increased total IGFBP3 expression in 
LNCaPTβRII cells, while it reversed DZ-50-induced 
N-cadherin decrease (Figure 3C). Smad4 expression was 
not affected by DZ-50 (Supplementary Figure 3).
DZ-50 decreased IGFBP3 expression in CAFs
Cell viability of CAFs derived from Patient 2 and 
9 (Supplementary Table 1) was decreased by DZ-50 in 
a dose- dependent manner (Figure 4A; Supplementary 
Figure 4C). CAFs derived from Patient 9 were more 
resistant to DZ-50 treatment compared to those from 
Patient 2 (Figure 4A; Supplementary Figure 4C). DZ-
50 (2µM) inhibited IGFBP3 mRNA expression in CAFs 
derived from Patient 2 and Patient 10 (Supplementary 
Table 1) after 6hrs, and 3/6hrs treatment, respectively 
(Figure 4B). The drug had no effect on IGFBP3 mRNA/
protein expression in CAFs derived from Patient 9 
(Supplementary Figure 4A and 4B). The highest IGFBP3 
mRNA level was detected in prostate tumor with the 
highest Gleason score (4+5) (Figure 4C). DZ-50 treatment 
decreased IGFBP3 protein expression in CAFs (derived 
from Patient 2 and 10), but had no significant effect on 
ZEB1, N-cadherin, β-catenin, or vimentin levels (Figure 
4D).
DZ-50 inhibited DU-145 and LNCaP cell 
migration in CAF co-culture
In order to recapture the stroma component of the 
prostate tumor microenvironment, co-cultures of CAFs 
and prostate cancer epithelial cells were used to evaluate 
the effect of DZ-50 on cell migration. As shown on Figure 
5 (panel A), co-culture of DU-145 and DU-145talin1 
cells with prostate CAFs promoted prostate cancer cell 
migration, an effect that was impaired by DZ-50 (2µM). 
The CAF-mediated-cell migration in the androgen-
sensitive cell lines LNCaPTβRII (Figure 5B), and LNCaP 
(Supplementary Figure 5), was significantly inhibited by 
DZ-50 treatment. In the LNCaPTβRII cells, the ability of 
TGF-β1 to directly promote prostate cancer cell migration 
was also blocked by DZ-50 (Figure 5B).
DISCUSSION
This study provides the first evidence on the impact of 
our lead quinazoline agent, DZ-50, on EMT reversion to the 
MET phenotype in different human prostate cancer cell lines 
and in co-culture cell models (with CAFs), via targeting 
IGFBP3. The drug-induced MET was prevented by talin1 
overexpression in DU-145 androgen-independent prostate 
cancer cells, in accord with recent evidence suggesting that 
talin1 loss impaired EMT and consequential acquisition 
of cell motility [28]. DU-145 talin1 overexpressing cells 
developed resistance to DZ-50-induced anoikis [24] and 
acquisition of the mesenchymal phenotype induced by 
talin1 overexpression was associated with the anoikis 
resistance [29]. In addition, phosphoinositide-generating 
enzyme, PIPKIγ, and talin1 together control the adhesion 
and phosphoinositide signaling that regulates EMT [28], 
indicating that important coupling enzymes in addition to 
talins are required for EMT induction. The involvement of 
talin1 in cadherin regulated cell-cell attachment is supported 
by evidence suggesting that a novel calpain-dependent 
proteolytic cleavage of talin1 results in the release of a 70-
kD C-terminal fragment that rescues the cell-cell adhesion 
formation [30]. One could thus easily argue that talin1 
overexpression might generate more calpain-dependent 
proteolytic cleaved protein, recruiting E-cadherin to the 
cell membrane. Interestingly enough, in DU-145 cells, 
E-cadherin was not upregulated by DZ-50, which could 
be due to posttranslational modification such as protein 
degradation. In that context one may consider that several 
E3 ubiquitin ligases are involved in EMT regulation, and 
genetic alterations of these ligases have been found in 
prostate cancer [31, 32].
TGF-β1 promotes prostate tumor migration, invasion 
and metastatic spread through navigating functional 
interactions within the tumor microenvironment [10]. Co-
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culture with CAFs promoted prostate cancer epithelial 
cell migration and invasion via TGF-β1, consistent 
with a TGF-β1-induced EMT phenotype, which was 
pharmacologically inhibited (by DZ-50). In the TGF-β1-
responsive LNCaPTβRII cells, DZ-50 promoted MET by 
downregulating nuclear IGFBP3, an action antagonized 
by TGF-β1. Considering that IGFBP3 promotes TGF-
β1-mediated EMT by activating critical transcriptional 
regulators, including Snail and ZEB1 in human esophageal 
epithelial cells [23], the DZ-50 targeting of nuclear IGFBP3 
could be driving the drug-induced MET. The present findings 
provide new insights into the ability of TGF-β1 to modify the 
response of prostate cancer cells to DZ-50. Mechanistically, 
TGF-β1 previously shown to upregulate IGFBP3 [23, 26], 
may directly antagonize the effect of DZ-50 on IGFBP3 and 
prevent pharmacologically-induced MET (schematically 
shown on Figure 5C). Functional silencing of IGFBP3 
in prostate cancer epithelial cells resulted in increased 
Figure 3: Effect of DZ-50 on nuclear IGFBP3 in LNCaPTβRII cells. Panel A, representative confocal images of IGFBP3 and 
E-cadherin localization in LNCaPTβRII cells. Cells were exposed to DZ-50 (24hrs), in the absence or presence of TGF-β1 (5ng/ml) and 
subjected to fluorescent labeling for IGFBP3, E-cadherin and DAPI. Magnification, X60. Panel B, Western blot analysis of subcellular 
fractions for IGFBP3 protein after treatment with DZ-50 (48hrs) in presence/absence of TGF-β1 (5ng/ml). Panel C, Western blot of 
E-cadherin, N-cadherin and IGFBP3 levels after DZ-50 exposure (4µM, 48hrs) in the presence/absence of TGF-β1. The blot is representative 
of three independent experiments.
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E-cadherin, while neither of the transcriptional repressors, 
Snail or ZEB1 mRNA expression was significantly affected 
(by IGFBP3 knockdown) begging the question as to its 
role in EMT-MET cycling. An alternative pathway through 
which IGFBP3 regulates EMT, might involve interaction 
of nuclear IGFBP3 with the E-cadherin DNA promoter. 
Such a possibility gains support from reports in other 
systems indicating the interaction of IGFBP3 with nuclear 
receptors (retinoid receptors, PPARγ and Nur77), as well 
as the histone-DNA complex [33]. Import of IGFBP3 into 
the nucleus is mediated by binding to importin-β (i.e., 
Karyopherin-β) to form the importin-α/β nuclear transport 
complex, sharing a common pathway with IGFBP5 [34–36]. 
The focus on nuclear localization of IGFBP3 takes particular 
significance as the nuclear protein (IGFBP3) has been 
previously associated with human prostate cancer recurrence 
[37]. TGF-β1 prevented the effect of DZ-50 on nuclear 
IGFBP3 and EMT reversal, supporting the involvement 
of nuclear IGFBP3 in promoting EMT [10], in accord 
with evidence that IGFBP3 enhanced TGF-β1-mediated 
fibroblast differentiation towards EMT [14]. Here we propose 
a new effect of DZ-50 on nuclear IGFBP3 mediating the 
pharmacologic reversion of EMT to MET in prostate cancer 
cells (Figure 5C). The impact of DZ-50 treatment on this 
nuclear transport dynamic is currently being investigated in 
pre-clinical models of prostate cancer progression.
In esophageal squamous cell carcinoma, IGFBP3 
promotes tumor progression in a subset of tumor cells with 
a concurrent high expression of CD44 [38]. CD44, a major 
cell surface hyaluronic acid receptor, is involved in invasion, 
metastasis and drug resistance in many human malignancies 
including prostate cancer [38, 39]. High CD44 expression 
is a characteristic of cancer stem cells functionally linked 
to prostate cancer metastasis [40]. Switch from CD44+ cell 
to EMT cell is regulated by TGF-β1-CD44 signaling as a 
critical step in prostate cancer cell metastasis [41]. Thus 
Figure 4: CAFs Response to DZ-50. Panel A, shows the effect of DZ-50 on cell viability in CAFs derived from Patient 2. DZ-50 
decreased cell viability in CAFs in a dose- and time-dependent manner, n=4; *p<0.05. Panel B, expression profile of IGFBP3 mRNA in 
CAFs derived from Patient 2 and 10 in response to DZ-50, n≥6; *p<0.05. Panel C, IGFBP3 mRNA expression in prostate tumors. Panel 
D, shows the expression profile for IGFBP3, N-cadherin, β-catenin, vimentin and ZEB1 proteins in patient-derived CAFs after DZ-50 
treatment (2µM, 24-48hrs).
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one can speculate on a potential engagement of IGFBP3 by 
the TGF-β1-CD44 signaling of EMT in prostate tumors. In 
addition, the functional contribution of IGFBP3 to prostate 
cancer cell apoptosis [42], involves the IGFBP3-mediated 
Figure 5: Effect of DZ-50 on CAF-mediated migration of prostate cancer cells. Panel A, shows fluorescent images of migrated 
DU-145 and DU-145talin1 cells co-cultured with CAFs in the absence/presence of DZ-50 (2µM; 24hrs) and respective numerical data from 
quantitative analysis. Panel B, shows fluorescent images of migrated LNCaPTβRII cells co-cultured with CAFs in the absence/presence of 
the drug (2µM; 24hrs), TGF-β1 (5ng/ml; 24 hrs), and TGF-β1NA (TGF-β1 neutralizing antibody; 500ng/ml); numerical data were analyzed 
as described in “Materials and Methods”; Magnification x40; *p<0.05. Panel C, schematic illustration of pathway via which DZ-50 dictates 
EMT to MET conversion and CAF-facilitated prostate cancer cell migration via targeting nuclear localization of IGFBP3.
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translocation of Nur77 from the nucleus to mitochondria 
[43]. Moreover while IGFBP3 enhanced doxorubicin-
induced apoptosis, it also promoted survival under serum 
starvation, indicating a dual role for IGFBP3 in human 
endothelial cells [44]. At the molecular level, IGFBP3 
activated SphK1 and led to S1P-dependent transactivation 
of EGFR in normal mammary epithelial and breast cancer 
cells [45, 46]. SphK1 activation by IGFBP3 has been 
implicated in resistance to chemotherapy-induced DNA 
damage by forming nuclear complexes with EGFR and 
DNA-PKcs [47]. The IGF axis is involved in prostate cell 
proliferation, differentiation and apoptosis [48, 49]. Clinical 
evidence has established a positive correlation between 
elevated IGF-1Rs in prostate stroma tissue and Gleason 
grade, and down-regulation of epithelial IGFBP3 in prostate 
cancer patients [50]. Positioning a role for IGFBP3 in the 
tumor microenvironment, elevated IGFBP3 in stroma 
tissue was found in pre-clinical models of prostate cancer 
resonating with the evidence in human prostate cancer 
specimens [23, 51].
Prostate stroma heterogeneity in prostate cancer 
could account for the differential response of CAFs 
(from different patients) to DZ-50. CAFs derived from 
high grade prostate tumor harboring the highest IGFBP3 
mRNA levels, exhibited resistance to the drug, compared 
to CAFs from low-grade tumors. The differences in the 
response of CAFs from patient 2 vs patient 9 to DZ-50, as 
well as the differential IGFBP3 mRNA expression among 
the six prostate tumors (from individual patients), could 
be driven by the stroma and tumor heterogeneity that 
characterizes prostate tumors and the microenvironment 
[52, 53]. Thus heterogeneity in tumor stroma constitution 
and its functional interaction with tumor epithelial 
cells may “calibrate” therapeutic sensitivity. A better 
understanding of functional interactions between 
fibroblasts and tumor epithelial cells, as mediated by 
IGFBP3, will define the role of stroma to therapeutic 
resistance in advanced prostate cancer [53].
Our findings taken together with clinical evidence 
that IGFBP3 promoter polymorphism contributes to 
prostate cancer risk [54, 55], and its potential biomarker 
value in prostate cancer patients [56], support the 
clinical significance of IGFBP3. This study enhances 
our understanding of a new dynamic in the prostate 
tumor stroma involving IGFBP3 as an EMT regulator, 
and its impact on the therapeutic response of cancer 
epithelial cells. The effect of the new agent, DZ-50, on 
MET induction and TGF-β1-mediated prostate tumor 
cell migration by targeting IGFBP3, may facilitate a new 
therapeutic optimization platform for the treatment of 
advanced CRPC.
MATERIALS AND METHODS
Cell cultures and drugs
Human prostate cancer cell lines PC-3, DU-145, 
LNCaP were obtained from the American Type Tissue 
Culture Collection (Rockville, MD). Primary prostatic 
CAFs are provided by Dr. S. Koochekpour (Roswell 
Park Cancer Institute, Buffalo, NY). The LNCaP cells 
overexpressing the TGF-β receptor II (LNCaPTβRII) [26], 
DU-145 cells overexpressing talin1 (DU-145 talin1) [57], 
and prostate cancer cells co-cultured with primary prostatic 
CAFs [58] have been established in our laboratory. DZ-50, 
a first-generation doxazosin quinazoline derivative was 
used as the novel therapeutic agent [25].
Antibodies
Antibodies against specific proteins were obtained 
as follows: The monoclonal antibody against N-cadherin 
from Abcam (San Francisco, CA); for E-cadherin from 
BD Biosciences (San Jose, CA); antibodies against 
the human β-catenin and vimentin from Cell Signaling 
Technology (Beverly, MA); monoclonal antibodies against 
ZEB1 and IGFBP3 were from the Bethyl Laboratories 
(Montgomery, TX) and Santa Cruz Biotechnology (Dallas, 
TX) respectively; the antibody against talin1 was obtained 
from EMD Millipore (Billerica, MA).
Western blot analysis
Cell lysates from prostate cells were subjected to 
Western blotting as previously described [58]. Subcellular 
fractionation was performed using NE-PER nuclear-
cytoplasmic fraction kit (Thermo Scientific, Rockford, 
IL). Protein samples were analyzed by SDS-PAGE 
and transferred to Hybond-C membranes (Amersham 
Pharmacia Biotech, Inc; Piscataway, NJ). Membranes 
were incubated with the respective primary antibody 
(4°C), and exposed to species-specific peroxidase-labeled 
secondary antibodies. Signal detection was achieved and 
visualized using a UVP Imaging System. Protein bands 
were normalized to GAPDH expression.
Cell viability assay
Cell viability was evaluated using the Thiazolyl Blue 
Tetrazolium bromide (MTT, Thermo Fisher Scientific, 
Waltham, MA) assay as previously described [8]. Briefly 
cells were seeded into 24-well plates and after grown to 
60% to 75% confluence, were treated with vehicle or DZ-
50 at indicated doses (DMSO, Sigma-Aldrich, St. Louis, 
MO). Absorbance was measured at 570nm and 690nm 
using μQuant Spectrophotometer (Biotech Instruments 
Inc., Winooski, VT).
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Quantitative RT-PCR analysis
RNA was extracted with the TRIzol reagent (Life 
Technologies, Waltham, MA), and RNA samples (1μg) 
were subjected to reverse transcription using the Reverse 
Transcription System (Promega, Madison, WI) [8]. 
TaqMan real-time RT-PCR (Life Technologies, Waltham, 
MA) analysis of the cDNA samples was conducted in an 
ABI7700 Sequence Detection System (Life Technologies, 
Waltham, MA) using the specific primers: E-cadherin 
(CDH1; Hs01023894_m1), N-cadherin (CDH2; Hs00983-
056_m1), Snail (SNAI1; Hs00195591_m1), Slug (SNAI2; 
Hs00161904_m1), Zeb1 (ZEB1; Hs00232783_m1), 
vimentin (VIM; Hs00185584_m1), IGFBP3 (IGFBP3; 
Hs00365742_g1), and 18S rRNA (4319413E; Applied 
Biosystems, Life Technologies, Waltham, MA). Data 
represent average values from three independent experiments; 
numerical data normalized to 18s rRNA.
RNA silencing
The siRNA knocking down IGFBP3 was obtained 
from Dharmacon (Lafayette, CO) with negative 
control sequence included. LNCaPTβRII cells were 
transfected either with a human IGFBP3 SMAT pool 
siRNA (GCUACAAAGUUGACUACGA; GAAAUG-
CUAGUGAGUCGGA; GCACAGAUACCCAGAACUU; 
GAAUAUGGUCCCUGCCGUA; 50 ng/ml) or with 
an NC pool siRNA (UGGUUUACAUGUCGACUAA; 
UGGUUUACAUGUUGUGUGA; UGGUUUACAUGU-
UUUCUGA; UGGUUUACAUGUUUUCCUA; 50 ng/ml;) 
in a solution containing DharmaFECT 3 Transfection 
Reagent (1µl/ml in antibiotic-free RPMI medium), at 37°C 
for 48hrs. IGFBP3 silencing at the mRNA and protein 
level was assessed by RT-PCR and Western blot analysis 
respectively. Transfected cells were treated with DZ-50 
(4µM) for 3hrs and RT-PCR assays were performed as 
above.
Immunofluorescent confocal microscopy
Cells were plated (1×105) on cover glasses in 6-well 
plates as previously described [8]. Cells were exposed to 
medium (RPMI1640 with 10% FBS) in the presence of 
DZ-50 (4 µM), TGF-β1 (5ng/ml), or in combination of 
the two agents. Following treatment, cells were fixed in 
4% paraformaldehyde and permeabilized with 0.1% Triton 
X-100 in sterile PBS. Fixed cells were incubated overnight 
with primary antibody specific for IGFBP3 and E-cadherin 
(Santa Cruz Biotechnology, Dallas, TX; BD Biosciences, 
San Jose, CA) at 4°C and the appropriate Alexa-Fluor 
(Life Technologies, Waltham, MA) fluorescent secondary 
antibody (1hr, room temperature). Slides were mounted 
using Vectashield mounting medium with DAPI (Vector 
Laboratories, Inc. Burlingame, CA) and were visualized 
using a FV1000 Confocal Microscope (Markey Cancer 
Center Core, University of Kentucky, Lexington, KY).
Cell migration assay
CellTracker Green CMFDA dye (5 μmol/L; 
Invitrogen, Waltham, MA) dissolved in DMSO were 
added to flask culturing CAF (45mins, 37°C) as previously 
described [58]. CellTracker Orange CMTML (Invitrogen, 
Waltham, MA) in 1640 RPMI was added to prostate cancer 
cells, DU-145, DU-145talin1 and LNCaPTβRII, (45 mins, 
37°C). Labeled cell suspensions of CAFs were placed 
into the 24-well plate included in the Biocat Matrigel 
Transwell Chamber (Corning, Bedford, MA). Labeled 
prostate cancer epithelial cells were seeded respectively 
in the transwell inserts placed (in 24-well plates) in the 
absence or presence of DZ-50, and/or TGF-β1 ligand (5 
ng/mL, R&D System, Minneapolis, MN), and TGF-β1 
neutralizing antibody (NA; R&D System, Minneapolis, 
MN). Invading prostate cancer cells were visualized 
using an epifluorescence Nikon Eclipse E600 microscope 
(Nikon, Melville, New York).
Statistical analysis
The Student t-test, one-way, or two-way ANOVA 
were performed using GraphPad Prism 6 software to 
determine the statistical significance of difference between 
means/treatments. All numerical data are presented as 
mean± SEM. Statistical significance was set at p < 0.05.
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